Results 81 to 90 of about 40,704 (273)

CYP2C19*2 allele carrier status and coronary in-stent restenosis : is there an association? [PDF]

, 2018
Background and objective: The CYP2C19*2 allele is associated with reduced clopidogrel bioactivation, increasing the risk of complications after percutaneous coronary intervention (PCI), particularly stent thrombosis. Recently published data suggests that
Azzopardi, Lilian M., Barbara, Christopher, Camilleri, Liberato, Fenech, Albert, Wirth, Francesca, Xuereb, Robert G., Zahra, Graziella   +6 more
core   +1 more source

Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450

British Journal of Clinical Pharmacology, EarlyView.
Aims To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel])
Vivek S. Purohit, Yeamin Huh, Martin E. Dowty, Anna Plotka, Alexandre Lejeune, Hindu Kalluru, Brian Hee   +6 more
wiley   +1 more source

Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence

Pharmacogenomics and Personalized Medicine, 2020
In patients undergoing percutaneous coronary intervention (PCI), the standard of care is dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin.
Megan N. Gower, Lindsay R Ratner, Alexis K. Williams, J. Rossi, G. Stouffer, Craig R. Lee   +5 more
semanticscholar   +1 more source

Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations

British Journal of Clinical Pharmacology, EarlyView.
Aims Voriconazole is extensively metabolized via cytochrome P450 (CYP) enzymes, predominantly CYP2C19 and CYP3A4. Drugs influencing the activity or expression of CYP enzymes can cause clinically relevant changes in the metabolism and voriconazole exposure. Metamizole is known to induce CYP3A4 and CYP2C19.
Simone D. Baan, Daan J. Touw, Marjolijn N. Lub‐de Hooge, Thijs H. Oude Munnink   +3 more
wiley   +1 more source

CYP2C19 polymorphism increases the risk of endometriosis [PDF]

Journal of Assisted Reproduction and Genetics, 2014
Estrogen metabolizing gene mutations can be associated with defective hormonal signaling leading to disease processes. Endometriosis is an estrogen dependent that can be influenced by defective signaling in the estrogen pathway.To evaluate the association of A/G 85952 CYP2C19 and A/G 937 HSD17B1 gene polymorphisms with endometriosis through the ...
Aline Amaro, Bianca Bianco, Amanda Sonnewend, Fernanda Abani Mafra, Denise Maria Christofolini, Caio Parente Barbosa   +5 more
openaire   +3 more sources

Pharmacogenetic Expression of CYP2C19 in a Pediatric Population

Journal of Personalized Medicine, 2022
Genetic variability in CYP2C19 may be associated with both lack of efficacy and toxicity of drugs due to its different metabolic status based on the presence of particular alleles. This literature review summarizes current knowledge relative to the association or treatment adaptation based on CYP2C19 genetics in a pediatric population receiving drugs ...
Marie Josette Déborah Pierre-François, Vincent Gagné, Ivan Brukner, Maja Krajinovic   +3 more
openaire   +2 more sources

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls

Pharmacogenomics (London), 2020
Pharmacogenetic variants can alter the mechanism of action (pharmacodynamic gene variants) or kinetic processes such as absorption, distribution, metabolism and elimination (pharmacokinetic gene variants).
Moataz Ellithi, Jordan F. Baye, R. Wilke
semanticscholar   +1 more source

Current trends in drug metabolism and pharmacokinetics. [PDF]

, 2019
Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication.
Abduljalil, Aghazadeh-Habashi, Aigrain, Aitman, Al Za'abi, Alegre, Alnaqeeb, Aspromonte, Babiskin, Baert, Bakke, Barnett, Bhattacharyya, Cang, Cannady, Cao, Cao, Capecchi, Chen, Chen, Chen, Chen, Chen, Chen, Chen, Cheng, Cheng, Crawford, Currie, De Lange, Dean, Deng, Di Paolo, Dietrich, Diliberto, Dluzen, Dowling, Dragin, Dreisbach, Duan, Edeogu, Edginton, El-Arabey, El-Kadi, EMA, Eum, Falany, Fang, FDA, Feng, Feng, Feng, Ferri, Fleming, Foti, Fox, Freedman, Frye, Fukami, Gaj, Gan, Gao, Gao, Gao, Gao, Gao, Ge, Genovese, Gingell, Gingell, Gong, Graham, Gufford, Guo, Guo, Guo, Guévin, Han, Harrison, Hartz, Hasegawa, He, He, He, He, He, Ho, Ho, Hou, Hsu, Hsueh, Hu, Hu, Hu, Huo, Hwang, Ito, Jacob, Jeong, Jeong, Jia, Jian, Jiang, Jiang, Jiang, Jiang, Jilek, Jilek, Johnson, Jorga, Jung, Kaivosaari, Kalthoff, Kaminsky, Kannan, Karibe, Kesisoglou, Kim, Kim, Knights, Kong, Kota, Kumar, Kurokawa, Lai, Lan, Lanchote, Lee, Lehouritis, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Liang, Lin, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Lopes-Rodrigues, Lu, Lu, Lu, Löfgren, Mano, Marchitti, Margolskee, Martin, Matsson, Mattick, Mazerska, Mei, Mencia, Meng, Min, Mitra, Miyajima, Müller, Nair, Nakano, Nakano, Nakano, Nebert, Nguyen, Niederalt, Nieto Montesinos, Niu, Notenboom, Nozaki, Ohtsuki, Ono, Oostendorp, Pan, Pan, Papageorgiou, Papageorgiou, Park, Pea, Pedersen, Pelkonen, Pellegrino, Pettersson Bergstrand, Qi, Qin, Qiu, Qiu, Raaska, Rives, Riviere, Roberts, Robey, Rocha, Rose, Routy, Rowland, Ruwali, Saini, Satoh, Savage, Scheer, Scheer, Schlender, Schmitt, Schneider, Seitz, Showande, Shu, Shu, Shu, Shugarts, Siu, Song, Staudinger, Strong, Suarez-Sharp, Suh, Suiko, Sukkummee, Sun, Sun, Sutliff, Takeda, Tan, Tan, Tao, Tatsumi, Teorell, Tsai, Tsang, Tsuchiya, Tsume, Tu, Ulldemolins, van Waterschoot, von Richter, Vugmeyster, Vuppugalla, Wagner, Wagner, Wagner, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wassenaar, Watanabe, Wei, Wijayakumara, Wilkinson, Wong, Wu, Xia, Xie, Xie, Xu, Xu, Xu, Xu, Xu, Xue, Yamagata, Yamaguchi, Yan, Yang, Yang, Yang, Ye, Yellepeddi, Yi, Yi, Yigitaslan, Yim, Yin, Yoshida, Yoshida, Yoshimi, Yu, Yu, Yu, Yu, Yu, Yu, Yu, Zakeri-Milani, Zanger, Zeng, Zeng, Zhai, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhao, Zhao, Zhao, Zhao, Zhou, Zhou, Zhou, Zhou, Zhou, Zhu, Zhu, Zhu, Zhuang, Zimmermann   +332 more
core   +1 more source

Pharmacology and relevant drug interactions of metamizole

British Journal of Clinical Pharmacology, EarlyView.
Metamizole is a frequently prescribed analgesic because of its favourable benefit/risk ratio compared with classic NSAIDs. However, increasing research shows that metamizole displays several drug interactions that are relevant to clinical practice. We reviewed the literature to summarize the pharmacology and most clinically relevant drug interactions ...
David J. Brinkman, Linda C. Hendriksen, Irma M. Rigter, Markus W. Hollmann   +3 more
wiley   +1 more source

Effect of High‐Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long‐lasting Inhibition of CYP2C19

Clinical pharmacology and therapy, 2020
In vitro, esomeprazole is a time‐dependent inhibitor of CYP2C19. Additionally, racemic omeprazole induces CYP1A2 and omeprazole and its metabolites inhibit CYP3A4 in vitro.
Taavi Kaartinen, A. Tornio, T. Tapaninen, Terhi Launiainen, N. Isoherranen, M. Niemi, J. Backman   +6 more
semanticscholar   +1 more source